Surmodics (NASDAQ:SRDX – Free Report) had its price target decreased by Needham & Company LLC from $47.00 to $43.00 in a report issued on Wednesday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Separately, StockNews.com lowered shares of Surmodics from a strong-buy rating to a buy rating in a research report on Wednesday, April 24th.
Check Out Our Latest Stock Report on SRDX
Surmodics Stock Performance
Hedge Funds Weigh In On Surmodics
Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Surmodics during the 4th quarter valued at approximately $163,000. Hillsdale Investment Management Inc. increased its holdings in Surmodics by 15.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock worth $166,000 after acquiring an additional 620 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after acquiring an additional 481 shares in the last quarter. Strs Ohio increased its holdings in Surmodics by 97.2% in the 4th quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after acquiring an additional 3,500 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in Surmodics in the 1st quarter worth $223,000. 96.63% of the stock is owned by hedge funds and other institutional investors.
Surmodics Company Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Recommended Stories
- Five stocks we like better than Surmodics
- How to Invest in Blue Chip Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- With Risk Tolerance, One Size Does Not Fit All
- Amazon Stands Tall: New Highs Are in Sight
- What Are Dividend Achievers? An Introduction
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.